|1.||Horowski, R: 2 articles (03/2006 - 01/2004)|
|2.||Speller, J M: 2 articles (01/2000 - 01/2000)|
|3.||Clarke, C E: 2 articles (01/2000 - 01/2000)|
|4.||Nowak, Gabriel: 1 article (04/2015)|
|5.||Zajdel, Paweł: 1 article (04/2015)|
|6.||Sapa, Jacek: 1 article (04/2015)|
|7.||Bednarski, Marek: 1 article (04/2015)|
|8.||Alonso-Navarro, Hortensia: 1 article (07/2013)|
|9.||García-Martín, Elena: 1 article (07/2013)|
|10.||Jiménez-Jiménez, Félix Javier: 1 article (07/2013)|
|1.||Parkinson Disease (Parkinson's Disease)
11/01/1991 - "The tolerance and efficacy of dopatherapy associated to lisuride or placebo were compared in 74 de novo patients with Parkinson's disease in a prospective randomized trial. "
05/01/1998 - "Efficacy of a low-dose subcutaneous lisuride infusion in Parkinson's disease."
01/01/2000 - "Well designed randomised controlled trials demonstrating efficacy and safety are required before the use of lisuride in later Parkinson's disease can be supported."
01/01/2000 - "No randomised controlled trials comparing lisuride with placebo in advanced Parkinson's disease with motor complications were found. "
01/01/1996 - "A study on the effect and tolerance of lisuride on Parkinson's disease."
09/01/2002 - "We demonstrate that patients receiving lisuride infusions experienced a significant reduction in both motor fluctuations and dyskinesia compared with patients receiving standard dopaminergic therapies. "
09/01/1985 - "Lisuride was discontinued in 26 patients because of adverse effects, including an organic confusional syndrome (15 patients), dyskinesias (five patients) and vasospasm (two patients). "
09/01/2002 - "This study indicates that continuous lisuride infusion can be beneficial for patients with advanced Parkinson's disease and reverse established motor fluctuations and dyskinesia."
01/01/1988 - "Side-effects and possible complications of that therapy are discussed as are some further indications for the clinical use of Lisuride in akinetic crisis, the neuroleptic malignant syndrome and in dyskinesias."
02/01/1991 - "Most patients continued to show improvement with respect to baseline assessment during chronic treatment but 23 developed dyskinesias, 'off' periods or both, which were difficult to control by changing the levodopa schedule, lisuride dose or both. "
|3.||Parkinsonian Disorders (Parkinsonism)
10/01/1989 - "A study of the cardiopressor effects of lisuride in the treatment of parkinsonism and pathological aging brain."
01/01/1992 - "Subcutaneous lisuride infusion should be taken into consideration in OPCA patients with signs of Parkinsonism if oral dopaminergic treatment has failed earlier on."
04/30/1987 - "Lisuride is a new effective agent in the combination treatment of advanced stages of parkinsonism."
08/30/1986 - "Psychiatric side-effects of high-dose lisuride therapy in parkinsonism."
01/01/1983 - "Less established, however, is the potential role of lisuride in treating patients in the early stages of parkinsonism and the long-term effects of lisuride. "
|4.||Restless Legs Syndrome (Restless Legs)
01/01/2006 - "Severity of RLS clearly improved during open-label and double-blind treatment with lisuride but became worse under placebo according to the International Restless Legs Syndrome Study Group Rating Scale (IRLS), RLS-6, and Clinical Global Impressions (CGIs) scales, and actigraphy assessments (periodic leg movement index) in the 1-week double-blind period. "
01/01/2006 - "Transdermal lisuride: short-term efficacy and tolerability study in patients with severe restless legs syndrome."
01/01/2006 - "Lisuride treatment of restless legs syndrome: first studies with monotherapy in de novo patients and in combination with levodopa in advanced disease."
01/01/1997 - "Results from these studies indicated that the DA-agonist lisuride, but not the S2-antagonist ritanserin, were able to antagonize the reserpine-induced tremor in a dose-related manner."
01/01/1981 - "In nine subjects with idiopathic, postencephalitic, or drug-induced parkinsonism, lisuride at a dosage of 0.05 to 0.15 mg intravenously caused an immediate improvement in tremor, rigidity, akinesia, and postural deformity, but also caused chorea and orofacial dyskinesia. "
03/28/1996 - "Effects of 7-nitroindazole, NG-nitro-L-arginine, and D-CPPene on harmaline-induced postural tremor, N-methyl-D-aspartate-induced seizures, and lisuride-induced rotations in rats with nigral 6-hydroxydopamine lesions."
|1.||Levodopa (L Dopa)
|2.||Dopamine Agonists (Dopamine Agonist)
|7.||Dihydroergocryptine (Dihydroergocryptine Mesylate)
|9.||1- Methyl- 4- phenyl- 1,2,3,6- tetrahydropyridine (MPTP)
|1.||Infusion Pumps (Infusion Pump)